150 related articles for article (PubMed ID: 26518726)
1. Sirtuins are Unaffected by PARP Inhibitors Containing Planar Nicotinamide Bioisosteres.
Ekblad T; Schüler H
Chem Biol Drug Des; 2016 Mar; 87(3):478-82. PubMed ID: 26518726
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3.
Sherstyuk YV; Ivanisenko NV; Zakharenko AL; Sukhanova MV; Peshkov RY; Eltsov IV; Kutuzov MM; Kurgina TA; Belousova EA; Ivanisenko VA; Lavrik OI; Silnikov VN; Abramova TV
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892271
[TBL] [Abstract][Full Text] [Related]
4. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
[TBL] [Abstract][Full Text] [Related]
5. A Simple, Sensitive, and Generalizable Plate Assay for Screening PARP Inhibitors.
Kirby IT; Morgan RK; Cohen MS
Methods Mol Biol; 2018; 1813():245-252. PubMed ID: 30097873
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
Badawy AA
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33063092
[TBL] [Abstract][Full Text] [Related]
7. Are poly(ADP-ribosyl)ation by PARP-1 and deacetylation by Sir2 linked?
Zhang J
Bioessays; 2003 Aug; 25(8):808-14. PubMed ID: 12879452
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
9. Strategies Employed for the Development of PARP Inhibitors.
Canan S; Maegley K; Curtin NJ
Methods Mol Biol; 2017; 1608():271-297. PubMed ID: 28695516
[TBL] [Abstract][Full Text] [Related]
10. Progress in the function and regulation of ADP-Ribosylation.
Hottiger MO; Boothby M; Koch-Nolte F; Lüscher B; Martin NM; Plummer R; Wang ZQ; Ziegler M
Sci Signal; 2011 May; 4(174):mr5. PubMed ID: 21610250
[TBL] [Abstract][Full Text] [Related]
11. Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics.
Kirby IT; Cohen MS
Curr Top Microbiol Immunol; 2019; 420():211-231. PubMed ID: 30242511
[TBL] [Abstract][Full Text] [Related]
12. Trapping Poly(ADP-Ribose) Polymerase.
Shen Y; Aoyagi-Scharber M; Wang B
J Pharmacol Exp Ther; 2015 Jun; 353(3):446-57. PubMed ID: 25758918
[TBL] [Abstract][Full Text] [Related]
13. High-Throughput Colorimetric Assay for Identifying PARP-1 Inhibitors Using a Large Small-Molecule Collection.
Kotova E; Tulin AV
Methods Mol Biol; 2017; 1608():299-312. PubMed ID: 28695517
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD(+)-dependent Sir2 histone/protein deacetylases.
Zhao K; Harshaw R; Chai X; Marmorstein R
Proc Natl Acad Sci U S A; 2004 Jun; 101(23):8563-8. PubMed ID: 15150415
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach.
Cui H; Kamal Z; Ai T; Xu Y; More SS; Wilson DJ; Chen L
J Med Chem; 2014 Oct; 57(20):8340-57. PubMed ID: 25275824
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.
Haikarainen T; Narwal M; Joensuu P; Lehtiö L
ACS Med Chem Lett; 2014 Jan; 5(1):18-22. PubMed ID: 24900770
[TBL] [Abstract][Full Text] [Related]
17. Weight Loss Is Associated With Increased NAD(+)/SIRT1 Expression But Reduced PARP Activity in White Adipose Tissue.
Rappou E; Jukarainen S; Rinnankoski-Tuikka R; Kaye S; Heinonen S; Hakkarainen A; Lundbom J; Lundbom N; Saunavaara V; Rissanen A; Virtanen KA; Pirinen E; Pietiläinen KH
J Clin Endocrinol Metab; 2016 Mar; 101(3):1263-73. PubMed ID: 26760174
[TBL] [Abstract][Full Text] [Related]
18. Novel pharmacological effects of poly (ADP-ribose) polymerase inhibitor rucaparib on the lactate dehydrogenase pathway.
Nonomiya Y; Noguchi K; Katayama K; Sugimoto Y
Biochem Biophys Res Commun; 2019 Mar; 510(4):501-507. PubMed ID: 30737031
[TBL] [Abstract][Full Text] [Related]
19. Sirt5 deacylation activities show differential sensitivities to nicotinamide inhibition.
Fischer F; Gertz M; Suenkel B; Lakshminarasimhan M; Schutkowski M; Steegborn C
PLoS One; 2012; 7(9):e45098. PubMed ID: 23028781
[TBL] [Abstract][Full Text] [Related]
20. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
